Search research articles
Contact Us
Filters
Showing results (451-460 of 481) with videos related to
Page
of 49
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 28, 2023
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy
Pierre Squifflet, Everardo D Saad, Sibylle Loibl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 23, 2022
Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer
Thomas Bachelot, Paul Cottu, Sylvie Chabaud, et al.
Nutrients
|
October 23, 2021
The Effect of Elevated Protein Intake on DNA Damage in Older People: Comparative Secondary Analysis of Two Randomized Controlled Trials
Agnes Draxler, Bernhard Franzke, Johannes T Cortolezis, et al.
The Lancet. Oncology
|
September 13, 2020
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
Nicholas C Turner, Belinda Kingston, Lucy S Kilburn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 30, 2020
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
Nancy U Lin, Virginia Borges, Carey Anders, et al.
BMC Medicine
|
April 13, 2025
Sexual dimorphism in the association of umbilical cord blood lipidome with abdominal fat in early childhood
Kothandaraman Narasimhan, Mya Thway Tint, Li Chen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 2, 2021
Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial)
Volkmar Mueller, Andrew Wardley, Elisavet Paplomata, et al.
Oncotarget
|
April 25, 2015
FKBPL: a marker of good prognosis in breast cancer
Laura Nelson, Hayley D McKeen, Andrea Marshall, et al.
Frontiers in Molecular Neuroscience
|
February 14, 2022
An <i>in vivo</i> Cell-Based Delivery Platform for Zinc Finger Artificial Transcription Factors in Pre-clinical Animal Models
Peter Deng, Julian A N M Halmai, Ulrika Beitnere, et al.
The Lancet. Oncology
|
May 9, 2017
Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial
Helena M Earl, Louise Hiller, Helen C Howard, et al.
Page
of 49
Search research articles
Search
Showing results (451-460 of 481) with videos related to
Sort By:
Page
of 49
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 28, 2023
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy
Pierre Squifflet, Everardo D Saad, Sibylle Loibl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 23, 2022
Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer
Thomas Bachelot, Paul Cottu, Sylvie Chabaud, et al.
Nutrients
|
October 23, 2021
The Effect of Elevated Protein Intake on DNA Damage in Older People: Comparative Secondary Analysis of Two Randomized Controlled Trials
Agnes Draxler, Bernhard Franzke, Johannes T Cortolezis, et al.
The Lancet. Oncology
|
September 13, 2020
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
Nicholas C Turner, Belinda Kingston, Lucy S Kilburn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 30, 2020
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
Nancy U Lin, Virginia Borges, Carey Anders, et al.
BMC Medicine
|
April 13, 2025
Sexual dimorphism in the association of umbilical cord blood lipidome with abdominal fat in early childhood
Kothandaraman Narasimhan, Mya Thway Tint, Li Chen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 2, 2021
Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial)
Volkmar Mueller, Andrew Wardley, Elisavet Paplomata, et al.
Oncotarget
|
April 25, 2015
FKBPL: a marker of good prognosis in breast cancer
Laura Nelson, Hayley D McKeen, Andrea Marshall, et al.
Frontiers in Molecular Neuroscience
|
February 14, 2022
An <i>in vivo</i> Cell-Based Delivery Platform for Zinc Finger Artificial Transcription Factors in Pre-clinical Animal Models
Peter Deng, Julian A N M Halmai, Ulrika Beitnere, et al.
The Lancet. Oncology
|
May 9, 2017
Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial
Helena M Earl, Louise Hiller, Helen C Howard, et al.
Page
of 49